Evidence map›Paper›PMID 36855049›Full record

ArticleAlzheimer's research & therapy2023

Brain reserve contributes to distinguishing preclinical Alzheimer's stages 1 and 2.

Zerrin Yildirim, Firuze Delen, David Berron, Hannah Baumeister, Gabriel Ziegler, Hartmut Schütze, Wenzel Glanz, Laura Dobisch, Oliver Peters, Silka Dawn Freiesleben and 35 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 18 institutions in 5 countries.

Zerrin YildirimDepartment of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Vakif Gureba Cad., Capa Kampusu Sehremini, Fatih, 34093, Istanbul, Turkey. yildirimzerrin@gmail.com.
Firuze DelenDepartment of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Vakif Gureba Cad., Capa Kampusu Sehremini, Fatih, 34093, Istanbul, Turkey.
David BerronInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Hannah BaumeisterGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Gabriel ZieglerInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Hartmut SchützeInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Wenzel GlanzGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Laura DobischGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Oliver PetersGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Silka Dawn FreieslebenCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
Luisa-Sophie SchneiderCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
Josef PrillerGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Eike Jakob SpruthGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Anja SchneiderGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Klaus FliessbachGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Jens WiltfangDepartment of Medical Sciences, Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal.
Björn-Hendrik SchottGerman Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
Dix MeiberthGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Katharina BuergerGerman Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse 17, 81377, Munich, Germany.
Daniel JanowitzInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany.
Robert PerneczkyGerman Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse 17, 81377, Munich, Germany.
Boris-Stephan RauchmannDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
Stefan TeipelGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Ingo KilimannGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Matthias H MunkGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Annika SpottkeGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Nina RoyGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Michael HenekaGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Frederic BrosseronGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Michael WagnerGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Sandra RoeskeGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Alfredo RamirezGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Michael EwersGerman Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse 17, 81377, Munich, Germany.
Peter DechentDepartment of Cognitive Neurology, MR-Research in Neurosciences, Georg-August-University Goettingen, Göttingen, Germany.
Stefan HetzerBerlin Center for Advanced Neuroimaging, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Klaus SchefflerDepartment for Biomedical Magnetic Resonance, University of Tübingen, 72076, Tübingen, Germany.
Luca KleineidamGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Steffen WolfsgruberGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Renat YakupovGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Matthias SchmidGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Moritz BergerInstitute for Medical Biometry Informatics, and Epidemiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Hakan GurvitDepartment of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, 34093, Istanbul, Turkey.
Frank JessenGerman Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
Emrah DuzelInstitute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
German Center for Neurodegenerative Diseases · DEOtto-von-Guericke University Magdeburg · DECharité - Universitätsmedizin Berlin · DEIstanbul University · TRUniversity of Bonn · DEUniversity of Göttingen · DECologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · DEFreie Universität Berlin · DEInstitute for Neurodegenerative Disorders · USLeibniz Institute for Neurobiology · DELMU Klinikum · DELudwig-Maximilians-Universität München · DEMunich Cluster for Systems Neurology · DETechnical University of Munich · DEUniversity Hospital Bonn · DEUniversity of Cologne · DEUniversity of Tübingen · DEZimmer Biomet (Germany) · DE

Funding

USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
NIA NIH HHS P30 AG066530
6 · The paper itself

Abstract

backgroundIn preclinical Alzheimer's disease, it is unclear why some individuals with amyloid pathologic change are asymptomatic (stage 1), whereas others experience subjective cognitive decline (SCD, stage 2). Here, we examined the association of stage 1 vs. stage 2 with structural brain reserve in memory-related brain regions.

methodsWe tested whether the volumes of hippocampal subfields and parahippocampal regions were larger in individuals at stage 1 compared to asymptomatic amyloid-negative older adults (healthy controls, HCs). We also tested whether individuals with stage 2 would show the opposite pattern, namely smaller brain volumes than in amyloid-negative individuals with SCD. Participants with cerebrospinal fluid (CSF) biomarker data and bilateral volumetric MRI data from the observational, multi-centric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study were included. The sample comprised 95 amyloid-negative and 26 amyloid-positive asymptomatic participants as well as 104 amyloid-negative and 47 amyloid-positive individuals with SCD. Volumes were based on high-resolution T2-weighted images and automatic segmentation with manual correction according to a recently established high-resolution segmentation protocol.

resultsIn asymptomatic individuals, brain volumes of hippocampal subfields and of the parahippocampal cortex were numerically larger in stage 1 compared to HCs, whereas the opposite was the case in individuals with SCD. MANOVAs with volumes as dependent data and age, sex, years of education, and DELCODE site as covariates showed a significant interaction between diagnosis (asymptomatic versus SCD) and amyloid status (Aß42/40 negative versus positive) for hippocampal subfields. Post hoc paired comparisons taking into account the same covariates showed that dentate gyrus and CA1 volumes in SCD were significantly smaller in amyloid-positive than negative individuals. In contrast, CA1 volumes were significantly (p = 0.014) larger in stage 1 compared with HCs.

conclusionsThese data indicate that HCs and stages 1 and 2 do not correspond to linear brain volume reduction. Instead, stage 1 is associated with larger than expected volumes of hippocampal subfields in the face of amyloid pathology. This indicates a brain reserve mechanism in stage 1 that enables individuals with amyloid pathologic change to be cognitively normal and asymptomatic without subjective cognitive decline.

Indexed as

Alzheimer DiseaseCognitive DysfunctionCognitive ReserveAgedAmyloidogenic ProteinsCerebral CortexHumansAmyloidogenic ProteinsAlzheimer’s disease (AD)Amyloid pathologic changeAß42/40Brain reserveCerebrospinal fluid (CSF)HippocampusMagnetic resonance imaging (MRI)Medial temporal lobeMemorySubjective cognitive decline (SCD)

Identifiers

PMID36855049
PMCPMC9972621
OpenAlexW4322718954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.